Experienced in Relapsed Refractory Multiple Myeloma (RRMM)

Pasquale L. Fedele

5Department Of Immunology And Allergy, 246 Clayton Road, 
Clayton, VIC, AU 
Experienced in Relapsed Refractory Multiple Myeloma (RRMM)
5Department Of Immunology And Allergy, 246 Clayton Road, 
Clayton, VIC, AU 
OverviewLocationsClinical Research

Overview

Pasquale Fedele practices in Clayton, Australia. Mr. Fedele is rated as an Experienced expert by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). His top areas of expertise are Febrile Neutropenia, Multiple Myeloma, Acute Monoblastic Leukemia (AmoL), and Non-Hodgkin Lymphoma.

His clinical research consists of co-authoring 35 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Relapsed Refractory Multiple Myeloma (RRMM).

Gender
Male

Locations

5Department Of Immunology And Allergy, 246 Clayton Road, Clayton, VIC, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2025
Intervention Type: Drug
Study Drugs: Ponatinib, Imatinib, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone
Study Phase: Phase 3

35 Total Publications

Indolent lymphoma: addressing the needs of survivors.
Indolent lymphoma: addressing the needs of survivors.
Journal: Leukemia & lymphoma
Published: January 29, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Fedele's expertise for a condition
ConditionClose
      View All 14 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile